|
|
Post by gwb on Dec 15, 2014 16:10:18 GMT -5
I wonder what this is all about ? Any guess ?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
December 15, 2014
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
MannKind Corporation
File No. 000-50865 - CF#31824
_____________________
MannKind Corporation submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the exhibits to a Form 10-Q filed on November 10, 2014.
Based on representations by MannKind Corporation that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:
Exhibit 10.1 through November 10, 2017 Exhibit 10.2 through November 10, 2017
Exhibit 10.3 through November 10, 2017
For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
Brent J. Fields
Secretary |
|
|
|
Post by nemzter on Dec 15, 2014 16:20:51 GMT -5
|
|
|
|
Post by bradleysbest on Dec 15, 2014 16:31:33 GMT -5
ALL YOU "SHARPIES", WHAT DOES THIS MEAN?
|
|
|
|
Post by kc on Dec 15, 2014 16:31:47 GMT -5
If you go back and research filings like this for ALNY www.sec.gov/Archives/edgar/data/1178670/999999999713012135/filename1.pdf and REGN this is exactly how Sanofi did it with them before buying shares of the company. TICK TICK TICK. PRETTY soon its Christmas or it this the MannKind Hanukkah gift to us all. I'm ready to celebrate early. Happy Hanukkah I wonder what this is all about ? Any guess ?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
December 15, 2014
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
MannKind Corporation
File No. 000-50865 - CF#31824
_____________________
MannKind Corporation submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the exhibits to a Form 10-Q filed on November 10, 2014.
Based on representations by MannKind Corporation that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:
Exhibit 10.1 through November 10, 2017 Exhibit 10.2 through November 10, 2017
Exhibit 10.3 through November 10, 2017
For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
Brent J. Fields
Secretary |
|
|
|
Post by bradleysbest on Dec 15, 2014 16:32:09 GMT -5
ALL YOU "SHARPIES", WHAT DOES THIS MEAN? |
|
|
|
Post by purge on Dec 15, 2014 16:35:46 GMT -5
I am going to go out on a limb here. It could mean something, or it could mean nothing.
|
|
|
|
Post by jpg on Dec 15, 2014 16:36:18 GMT -5
To the best of my knowledge these secret orders are always good news or at worst neutral. For obvious reasons (lawsuits...) I have never heard of one being negative.
JPG
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 15, 2014 16:42:25 GMT -5
It means they received approval for confidential treatment that was requested on the forms in their latest 10-Q.
As a reminder, these were the sections where confidentiality was requested:
10.1† License and Collaboration Agreement, dated as of August 11, 2014, by and among MannKind Corporation, Technosphere International C.V.,
MannKind Netherlands B.V. and Sanofi-Aventis Deutschland GmbH.
10.2† Supply Agreement, dated as of August 11, 2014, by and between MannKind Corporation and Sanofi-Aventis Deutschland GmbH.
10.3† Supply Agreement, dated as of July 31, 2014, by and between MannKind Corporation and Amphastar France Pharmaceuticals S.A.S
Basically it means that everything that was listed as [...***...] was approved.
|
|
|
|
Post by beardawg on Dec 15, 2014 17:53:57 GMT -5
Basically it means that everything that was listed as [...***...] was approved. That's what I got out of it also. Nothing that wasn't already known from reading the 10Q. It had many things *****'d out and we filed for and now have approval to keep it that way. No biggie. |
|
|
|
Post by BlueCat on Dec 15, 2014 20:31:50 GMT -5
Fugacity, I think you also caught it right on ST. Seems to me basically that they don't want to tip their hand to pricing, etc before launch. Which is pretty much what they've been telling us.
If there is more in the works that was *****, that'd be great too.
Otherwise, in my fantasy, Mann would announce something tomorrow for Hanukah. Or he'd have a Christmas revenge after that HF CRL debacle.
But truly. I think we're cruising until New Year with EOY tax loss sales. Probably nobody wants a run up and big profit before then, let alone the fact that we haven't launched yet.
Though - curiously - for those shorts - if they exit now at low price, but still at a loss - that may perhaps help them with taxes vs. waiting to 2015 and increased risk and unknown losses in New Year.
|
|
|
|
Post by kc on Dec 15, 2014 22:49:29 GMT -5
The miracle of Hanukkah is upon us.
|
|
|
|
Post by babaoriley on Dec 16, 2014 2:00:43 GMT -5
I took a look, most (if not all) of the stuff redacted has to do with numbers, such as volume of orders for insulin from MNKD to Amphastar. They do not want to tip their hand to how strongly (or weakly) they believe in the early market acceptance of Afrezza. Stuff we'd all like to know and that Spiro can find out by just whistlin' for his girls - Roberta or Leona Bay.
|
|
|
|
Post by spiro on Dec 16, 2014 8:45:46 GMT -5
it is Spiro's opinion that within 6 month's of launch, there could be a serious shortage of Afrezza. Shortly after this explosive launch of Afrezza, SNY and MNKD will announce aggressive production line expansion. BTW, the Danbury plant is not big enough. . But it may just be SNY making these announcements.
|
|
